Cadence resubmits NDA for intravenous paracetamol
This article was originally published in Scrip
Executive Summary
Cadence Pharmaceuticals has resubmitted its NDA for its intravenous formulation of paracetamol, Ofirmev (acetaminophen); following a US FDA complete response letter it received in February (scripnews.com, 12 February 2010).